Testa Advances in Drug Research

1. Auflage 2013
ISBN: 978-1-4832-6688-6
Verlag: Elsevier Science & Techn.
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, Band Volume 21, 312 Seiten, Web PDF

Reihe: Advances in Drug Research

Advances in Drug Research, Volume 21 comprises three chapters that deal with the general subject, specific therapeutic class, and chemical family of diverse drugs. The first chapter of this book discusses the absorption and distribution of drugs in the lymphatic system. A presentation of the anti-infective quinolones is provided in Chapter 2, while the design and therapeutic potential of peptides are elaborated in Chapter 3. Other topics covered include lymphotropic carriers and the lymph uptake mechanism; basis of circulation in lymphatic transport of molecules through various routes of administration; and general aspects and characteristics of quinolone antibacterial agents. The mode of action and mechanisms of resistance of quinolones; potent agonists and antagonists of peptides; and inhibitors of atrial natriuretic factor-degrading enzymes are also deliberated in this text. This publication is valuable to drug researchers and students interested in advances in drugs.

Autoren/Hrsg.

Testa, Bernard

Inhaltsverzeichnis

1;Front Cover;1
2;Advances in Drug Research;4
3;Copyright Page;5
4;Table of Contents;6
5;CONTRIBUTORS;8
6;PREFACE: "POKING THE FIRE";10
7;Chapter 1. Drug Targeting Towards the Lymphatics;14
7.1;1 Introduction;15
7.2;2 The Lymphatic System and Lymphatic Circulation;16
7.3;3 Lymphotropic Carriers and the Lymph Uptake Mechanism;18
7.4;4 Properties of Drug–Carrier Complexes;21
7.5;5 Basis of Circulation in Lymphatic Transport of Molecules via Various Routes of Administration;23
7.6;6 Lymphatic Delivery by Gastrointestinal Drug Dosing;27
7.7;7 Lymphatic Delivery by Parenteral Drug Administration;42
7.8;8 Conclusions and Speculation;46
7.9;References;48
8;Chapter 2. Recent Developments in the Field of Quinolone Antibacterial Agents;52
8.1;1 Introduction;55
8.2;2 General Aspects and Characteristics;57
8.3;3 Chemical Variations and Biological Activity;67
8.4;4 Compounds on the Market and Under Development;92
8.5;5 Mode of Action and Mechanisms of Resistance;131
8.6;6 Perspectives;142
8.7;References;143
9;Chapter 3. Design and Therapeutic Potential of Peptides;158
9.1;1 Introduction;160
9.2;2 Identification of the Minimum Active Fragment;165
9.3;3 Increasing the Enzymic Stability of Peptides;169
9.4;4 Potent Agonists and Antagonists of Peptides;183
9.5;5 Inhibitors of the Enkephalin-degrading Dipeptidyl Carboxypeptidase (Enkephalinase);220
9.6;6 Inhibitors of Atrial Natriuretic Factor-degrading Enzymes;223
9.7;7 Angiotensin-converting Enzyme Inhibitors;227
9.8;8 Renin Inhibitors;240
9.9;9 Non-peptide Antagonists of Angiotensin II;252
9.10;10 Non-peptide Antagonists of CCK and Gastrin;254
9.11;11 Delivery of Therapeutic Peptides;260
9.12;12 Summary and Recent Developments;268
9.13;Acknowledgement;273
9.14;References;273
10;SUBJECT INDEX;300
11;CUMULATIVE INDEX OF AUTHORS;308
12;CUMULATIVE INDEX OF TITLES;310